Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Sera Prognostics, Inc.NASDAQ: SERA

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was $0.

Context

  • Income tax expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Income tax expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Income Tax Expense vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Income tax expense amounts to 0.0% of revenue for SERA, versus a peer median of 0.0%.
SERA Competitors
Income Tax Expense for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
APYXApyx Medical CorporationLTM Mar 2026$364K USD+46.8%-9.7%0.7%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$170.54K CAD+63.3%+18.9%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$41K USD+57.7%—0.1%
SERASera Prognostics, Inc.LTM Mar 2026$0 USD——0.0%
SRZNSurrozen, Inc.LTM Mar 2026$0 USD——0.0%
HURATuHURA Biosciences, Inc.LTM Mar 2026$0 USD———
LUCDLucid Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$0 USD———
STSSSkyAI, Inc.LTM Mar 2026$0 USD+100.0%—0.0%
Peer median (excluding SERA) —+60.5%+4.6%0.0%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue82K268K306K77K81K
Cost of Revenue37K193K210K82K164K
Gross Profit45K75K96K(5K)(83K)
Gross Margin54.9%28.0%31.4%-6.5%-102.5%
Research & Development11.02M14.24M15.23M14.73M13.17M
Selling, General & Admin24.42M31.48M24.69M21.9M23.25M
Operating Expenses35.44M45.73M39.92M36.63M36.42M
Depreciation & Amortization659K756K900K833K940K
EBITDA(33.6M)(43.37M)(35.29M)(32.04M)(30.98M)
EBITDA Margin-40980.5%-16182.5%-11531.7%-41606.5%-38245.7%
Operating Income(35.4M)(45.65M)(39.82M)(36.64M)(36.5M)
Operating Margin-43164.6%-17034.3%-13013.4%-47577.9%-45066.7%
Interest Income145K456K1.64M2.75M4.59M
Interest Expense746K61K55K28K9K
Other Income / Expenses386K1.47M3.58M3.74M4.58M
Income Before Tax(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Pre-Tax Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
Income Tax Expense00000
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Net Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
EPS (Basic)(1.18)(1.43)(1.16)(0.99)(0.67)
EPS (Diluted)(1.18)(1.43)(1.16)(0.99)(0.67)
Weighted Avg Shares30.77M30.94M31.2M33.16M47.66M
Weighted Avg Shares (Diluted)30.77M30.94M31.2M33.16M47.66M

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.